Abnova Taiwan Corp
Abnova Taiwan Corp has a strong liquidity position, with a current ratio of 17.02, indicating a significant ability to cover short-term liabilities with its current assets. The company's price-to-book ratio is 1.05, suggesting that the market value is slightly above the book value. However, the company's return on equity and return on assets are both negative at -0.09%, indicating poor profitability relative to its equity and total assets. The company's profitability is weak, with a net income of -1,141,000 TWD and an operating income of 14,224,000 TWD. The gross profit margin is 44.35%, which is relatively high, but the net loss suggests that operating expenses and other costs are eroding profitability. The company's debt-to-equity ratio is 0.01, indicating a low level of financial leverage and minimal debt burden. Abnova Taiwan Corp's revenue is primarily concentrated in Taiwan, the Americas, and Europe. The company's revenue concentration in these regions may expose it to regional economic fluctuations and regulatory changes. The company's products are mainly traded in these regions, which may affect its revenue stability and growth potential. The company's growth trajectory is mixed. The current fiscal year's revenue is 351,299,000 TWD, and the outlook for the next fiscal year is not provided. The company's operating cash flow is negative at -4,192,000 TWD, and its free cash flow is also negative at -30,568,000 TWD, indicating that the company is not generating sufficient cash from operations to fund its activities. The capital expenditure is -3,542,000 TWD, suggesting that the company is not investing heavily in new projects or assets. The risk assessment for Abnova Taiwan Corp indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags. The dilution potential is low, and the company has not made any recent adjustments to its valuation metrics. The company's financial structure is stable, with a low debt-to-equity ratio and a strong current ratio. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's last actual EPS was 0.97 TWD, and its last actual revenue was 475,073,000 TWD. There are no notable recent filings or transcripts that suggest significant changes in the company's strategy or operations.
Business. Abnova Taiwan Corp is a Taiwan-based company engaged in the manufacturing and sales of antibodies and proteins, primarily used in medical testing reagents, agricultural testing, industrial purification, and medical treatment.
Classification. Abnova Taiwan Corp is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Biotechnology & Medical Research industry with a confidence level of 0.92.
- Abnova Taiwan Corp has a strong liquidity position with a current ratio of 17.02.
- The company's profitability is weak, with a net loss of 1,141,000 TWD and a negative return on equity of -0.09%.
- Revenue is primarily concentrated in Taiwan, the Americas, and Europe, which may expose the company to regional economic fluctuations.
- The company's growth trajectory is mixed, with negative operating and free cash flows indicating insufficient cash generation from operations.
- The company has low liquidity and dilution risks, with no immediate filing-based flags detected.
- --
- # RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.